These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 35451036)

  • 21. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
    Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
    Front Immunol; 2021; 12():786554. PubMed ID: 35003104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
    Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
    Front Immunol; 2021; 12():737083. PubMed ID: 34539673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.
    Duarte LF; Gálvez NMS; Iturriaga C; Melo-González F; Soto JA; Schultz BM; Urzúa M; González LA; Vázquez Y; Ríos M; Berríos-Rojas RV; Rivera-Pérez D; Moreno-Tapia D; Pacheco GA; Vallejos OP; Hoppe-Elsholz G; Navarrete MS; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Bueno SM; Kalergis AM
    Front Immunol; 2021; 12():742914. PubMed ID: 34659237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
    Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
    Front Immunol; 2021; 12():796482. PubMed ID: 35111162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The level of protective post-vaccination antibodies in NIPH-NIH employees after administration of Pfizer vaccine against COVID-19.
    Rastawicki W; Płaza K
    Przegl Epidemiol; 2021; 75(1):3-13. PubMed ID: 34328282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA vaccine protection against SARS-CoV-2 in rhesus macaques.
    Yu J; Tostanoski LH; Peter L; Mercado NB; McMahan K; Mahrokhian SH; Nkolola JP; Liu J; Li Z; Chandrashekar A; Martinez DR; Loos C; Atyeo C; Fischinger S; Burke JS; Slein MD; Chen Y; Zuiani A; Lelis FJN; Travers M; Habibi S; Pessaint L; Van Ry A; Blade K; Brown R; Cook A; Finneyfrock B; Dodson A; Teow E; Velasco J; Zahn R; Wegmann F; Bondzie EA; Dagotto G; Gebre MS; He X; Jacob-Dolan C; Kirilova M; Kordana N; Lin Z; Maxfield LF; Nampanya F; Nityanandam R; Ventura JD; Wan H; Cai Y; Chen B; Schmidt AG; Wesemann DR; Baric RS; Alter G; Andersen H; Lewis MG; Barouch DH
    Science; 2020 Aug; 369(6505):806-811. PubMed ID: 32434945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
    Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
    mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.
    Bošnjak B; Odak I; Barros-Martins J; Sandrock I; Hammerschmidt SI; Permanyer M; Patzer GE; Greorgiev H; Gutierrez Jauregui R; Tscherne A; Schwarz JH; Kalodimou G; Ssebyatika G; Ciurkiewicz M; Willenzon S; Bubke A; Ristenpart J; Ritter C; Tuchel T; Meyer Zu Natrup C; Shin DL; Clever S; Limpinsel L; Baumgärtner W; Krey T; Volz A; Sutter G; Förster R
    Front Immunol; 2021; 12():772240. PubMed ID: 34858430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].
    Özgür D; Tütüncü EE
    Mikrobiyol Bul; 2022 Jan; 56(1):36-48. PubMed ID: 35088958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
    He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
    Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity.
    Scaglione A; Opp S; Hurtado A; Lin Z; Pampeno C; Noval MG; Thannickal SA; Stapleford KA; Meruelo D
    Front Immunol; 2021; 12():719077. PubMed ID: 34394127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
    Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Waning antibodies from inactivated SARS-CoV-2 vaccination offer protection against infection without antibody-enhanced immunopathology in rhesus macaque pneumonia models.
    Li D; Luan N; Li J; Zhao H; Zhang Y; Long R; Jiang G; Fan S; Xu X; Cao H; Wang Y; Liao Y; Wang L; Liu L; Liu C; Li Q
    Emerg Microbes Infect; 2021 Dec; 10(1):2194-2198. PubMed ID: 34736354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19].
    Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P
    Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals.
    Fraley E; LeMaster C; Geanes E; Banerjee D; Khanal S; Grundberg E; Selvarangan R; Bradley T
    BMC Med; 2021 Jul; 19(1):169. PubMed ID: 34304742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficient Maternofetal Transplacental Transfer of Anti- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Antibodies After Antenatal SARS-CoV-2 BNT162b2 Messenger RNA Vaccination.
    Rottenstreich A; Zarbiv G; Oiknine-Djian E; Zigron R; Wolf DG; Porat S
    Clin Infect Dis; 2021 Nov; 73(10):1909-1912. PubMed ID: 33822014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
    Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
    Front Immunol; 2021; 12():690698. PubMed ID: 34276681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.